Wegovy and Ozempic (semaglutide) associated with reduction in alcohol addiction

Cost, patents, and access

• Manufacturing cost of semaglutide is claimed to be very low (on the order of dollars per month), with high prices attributed to health-system pricing rather than production cost.
• Some expect complex peptide manufacturing to delay cheap generics even after patent expiry; others argue generics will appear quickly given the profit incentive.

Effectiveness, relapse, and lifelong use

• Very strong appetite and weight-loss effects reported; some frame GLP-1 agonists as near-“utopic” or vitamin-like for modern metabolism.
• Major concern: stopping often leads to regaining a large fraction of lost weight within a year; aggregate data suggest ~2/3–70% regain, though some weight tends to stay off.
• Debate over whether these drugs should be seen like lifelong treatments for hypertension/diabetes (just keep taking them) vs a temporary aid that must be paired with durable behavior change.

Side effects and long-term safety

• Reported/feared issues: loss of muscle mass, bone density, tendon/ligament weakness, bowel/GI problems, possible thyroid risk for some GLP-1s.
• Others argue much of the muscle/bone loss is typical of rapid weight loss by any method, and long-term GLP-1 use in diabetics suggests no dramatic undiscovered harms so far.
• Concern about rapid weight regain after discontinuation and its health impact is raised but data are described as incomplete.

Mechanisms, addiction, and behavior

• Thread topic emphasizes reduced alcohol and possibly other addictive behaviors; some see this as transformative for multiple addictions.
• Questions about whether addiction benefits persist after stopping, or simply shift once the drug is removed, remain open/unclear.
• Some worry about personality or motivational changes when “messing with fundamental hormones.”

Lifestyle, ethics, and society

• Strong disagreement over “just eat less / walk more” vs recognition that biological, environmental, and psychosocial factors make sustained weight loss extremely difficult.
• Obesity is increasingly framed by some as an addiction-like, trauma-linked, or neurodevelopmentally influenced condition rather than a moral failing.
• Fears that powerful food/alcohol industries will lobby against widespread GLP-1 use; others note pharma is equally powerful on the opposite side.
• Large potential population-level benefits (fewer cardiac events, diabetes, liver fat, etc.) are cited, leading some to argue governments should subsidize access.